Geometric mean fold rises to V. cholerae O1 Inaba and number who develop ≥ 4 fold rises from baseline after 14 and 28 day dosing intervals.*

* Median baseline titers were used for each age group (160 cut off for adults, 80 for children)a Geometric mean fold (GMF) rise from baseline to 14 days after dose 2b Number of participants with ≥ 4 fold rise in titers from baseline to 14 days after dose 2c p values comparing GMF-rise from baseline to 14 days after dose 2 between 14 days and 28 days interval groupsd p values comparing ≥4-fold rise from baseline to 14 days after dose 2 between 14 days and 28 days interval groupsGeometric mean fold rises to V. cholerae O1 Inaba and number who develop ≥ 4 fold rises from baseline after 14 and 28 day dosing intervals.*

* 各年龄组均采用基线抗体滴度中位数（成人截断值为160，儿童为80）
a) 第2剂接种后14天较基线的几何平均滴度倍数（Geometric mean fold, GMF）增长
b) 第2剂接种后14天，抗体滴度较基线增长≥4倍的受试者人数
c) 比较接种间隔为14天与28天组的第2剂接种后14天基线至滴度几何平均倍数增长的p值
d) 比较接种间隔为14天与28天组的第2剂接种后14天抗体滴度较基线增长≥4倍的p值
针对霍乱弧菌O1 Inaba（V. cholerae O1 Inaba）血清型的几何平均滴度倍数增长，以及在14天和28天给药间隔下，受试者抗体滴度较基线增长≥4倍的人数。